Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
AIM ImmunoTech ( (AIM) ) has provided an update.
AIM ImmunoTech Inc. has implemented a Cash Conservation Plan where independent directors receive their compensation entirely in company stock instead of cash, aligning with the strategy to enhance shareholder value and support clinical progress. Executives have similarly adjusted their compensation, underlining their commitment to the company’s long-term goals and belief in Ampligen’s potential in critical medical fields.
For detailed information about AIM stock, go to TipRanks’ Stock Analysis page.
